Management of bevacizumab toxicity for cancer therapy / 国际肿瘤学杂志

Bevacizumab is an efficient and low-toxicity monoclonal antibody towards serum ventricular endothelial growth factor.At present,bevacizumab has been approved by FDA to use clinically for kinds of cancer,such as colorectal cancer,lung cancer,kidney cancer and breast cancer.As more and more patients received bevacizumab cliniclly,it's toxicities are also focused on increasingly.

Study of Diagnostic Criteria for Gestational Diabetes Mellitus / 中华围产医学杂志

0.05), but there were significant differesnces compared with the control group ( P